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To the Editor: ST-segment elevation is the most important char-
cteristic for the diagnosis of Brugada syndrome (BrS). The
onsensus Report of Brugada Syndrome defined type 1 electro-
ardiogram (ECG) (coved-type ST-segment elevation 0.2 mV
ith a negative T-wave in the right precordial lead) is diagnostic
or BrS (1,2). Although the standard ECG recording of the right
recordial leads at the fourth intercostal space (ICS) sometimes
ails to reveal type 1 ECG, additional recording of leads V1 and V2
t high (third and second) ICS increases the sensitivity for
etecting type 1 ECG (3,4).
ST-segment elevation in BrS is believed to represent abnormal
epolarization at the right ventricular outflow tract (RVOT) (3).
owever, the relationship between ECG recording site (standard
nd high ICS recording) and the anatomical position of the
VOT is still unclear. Accordingly, we examined the relationship
etween the lead positions of type 1 ECG and the location of the
VOT in patients with BrS.
We examined 60 patients with BrS (59 men; 47  12 years of
ge). We defined BrS based on the Second Consensus Report of
rugada Syndrome (2). Cardiac catheterization, electrophysiologic
tudy, and genetic analysis were performed according to the
rotocol approved by the ethics committee of Okayama University.
ritten informed consent was obtained from all patients. Cardiac
atheterization and ECG recording were performed simulta-
eously in all patients. The ECG was recorded at the additional
hird and standard fourth ICS in leads V1 and V2 with fluoro-
copically visible electrodes. Anatomical location of the RVOT
as determined under fluoroscopic images, with right ventriculog-
aphy performed in the right anterior oblique (RAO) view. We
etermined the location of the RVOT as being below the pulmo-
ary valve and above the anterior border of the tricuspid valve in
he end-diastole and -expiration phase. We examined the relation-
hips between the location of the RVOT and the position of leads
anifesting type 1 ECG. For detailed analysis of lead position, we
ade an 8-segment model of the right ventricle in RAO view. We
nalyzed the lead position and appearance of type 1 ECG at
aseline conditions. If patients did not have type 1 ECG in any
eads at baseline, we used an intravenous injection of a pure
odium-channel blocker, pilsicainide (n  39). Genetic screening
evealed that SCN5A mutation was present in 5 of 39 patients
12.8%).
Anatomic correlation of the RVOT and the locations of the
hird and fourth ICS were variable in each patient (Figs. 1A and 1B).
igure 1A shows an example of 1 patient in whom the RVOT was eocated at the fourth ICS and type 1 ECG was recorded in leads
1 and V2 at both the third and fourth ICS. Figure 1B shows an
xample of another patient in whom the RVOT corresponded
o the third ICS, and the fourth ICS coincided with inflow to
he anterior free wall of the right ventricle. Type 1 ECG was
ecorded only by the third ICS electrode in this patient.
verall, type 1 ECG was recorded in leads that corresponded
ith the RVOT.
Figure 1C shows the distribution of location of ECG leads with
nd without type 1 ECG. The location of the RVOT corre-
ponded to the V1 and V2 leads at the fourth ICS in 11 patients
18.3%) and at the third ICS in 49 patients (81.7%). In 9 of 11
atients (82%) in whom the fourth ICS represented the RVOT,
ype 1 ECG was obtained at the fourth ICS. However, 41 of 49
atients (84%) in whom the third ICS represented the RVOT did not
how type 1 ECG at the fourth ICS, but it was shown at the third
CS instead. Accordingly, most of the ECG leads manifesting type 1
ere distributed at the RVOT (p  0.0001). Documented VF
n  12), syncope (n  10), family history of sudden cardiac death
n  19), induced ventricular fibrillation with programmed electrical
timulation (n 30), presence of SCN5Amutation, and spontaneous
ype 1 ECG (n  21) were not related to the location of the ECG
eads corresponding with the RVOT.
In the present study, we showed that the RVOT determines
he manifestation of type 1 ECG in patients with BrS. And the
elationship between the position of the leads and the RVOT
as variable in individual cases. Abnormal repolarization is
hought to be associated with the RVOT in BrS. However, the
xact anatomical location of the formation of type 1 ECG has
ot been fully examined yet. Because the V1 and V2 leads at the
tandard fourth ICS were not associated with the RVOT in
pproximately 80% of patients with BrS, the recording of
dditional V1 and V2 leads at the third ICS improved the
etection of type 1 ECG in BrS.
Previous basic studies have shown that the transient outward
urrent (Ito) is most prominent in the RVOT region of the
entricular myocardium, giving rise to a more prominent action
otential notch in this region, which is responsible for inscription
f the accentuated J-wave or ST-segment elevation in this lead
acing this region of the right ventricle (5).
In summary, our results show that positioning of ECG elec-
rodes at the RVOT can detect type 1 ECG in patients with BrS.
he ICS, which is associated with the RVOT, can be different in
ach patient.
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Figure 1 Detection of Type 1 ECG in the RVOT
(A) A 62-year-old male patient with recurrent unknown syncope attacks. (B) A 17-year
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2006;29:1130–59.Letters to the Editorxercise-Induced
roponin Elevation
ot Necessarily a Benign Phenomenon
n their comprehensive review of exercise-induced cardiac tropo-
in elevation, Shave et al. (1) come to the conclusion that this is a
enign phenomena most likely related to leakage of troponin from
he cardiac myocyte membrane rather than myocyte necrosis—the
sual cause of troponin elevation. In the absence of long-term
ollow-up of elite ultra-endurance athletes, this conclusion should
e viewed with caution. There is increasing evidence that, in some
thletes, participation in multiple extreme endurance events over a
ong period of years can lead to abnormal right ventricular (RV)
nlargement, dysfunction, and—more ominously—potentially le-
hal arrhythmias (2–4). Such athletes are clinically and genetically
istinct from those suffering from familial arrhythmogenic RV
ysplasia/cardiomyopathy (5). An appropriate terminology for
uch individuals is “exercise-induced right ventricular dysplasia”
2–5). A plausible hypothesis for this syndrome is that extreme
ndurance exercise places a strain on the RV that on occasions
eads to myocardial necrosis, albeit small, as reflected in post-
xercise elevated troponin levels. The cumulative effect of repeated
pisodes of necrosis can eventually lead to sufficient fibrosis to
esult in RV dysfunction and to act as a substrate for potentially
ethal arrhythmias. How prevalent exercise-induced RV dysplasia
s and whether there is a genetic predisposition to the condition
emains to be determined.
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eply
e appreciate Dr. Harper’s interest in our recent report (1). Dr.
arper suggests that without reassuring evidence from longitudi-
al studies it is possible that ultra-endurance exercise can produce
variant of right ventricular cardiomyopathy and suggests that the
levated cardiac troponin (cTn) observed after exercise are not
enign. From a historical viewpoint, ultra-endurance events are
ot new. At the turn of the last century walking and running
ontests of several days duration were popular spectator events and
aised concerns similar to those of Dr. Harper, but concerns about
icyclists’, runners’, and rowers’ hearts were never documented (2).
ight ventricular enlargement from endurance activity is not unusual
ut is rather one of the expected adaptations from exercise training.
ndeed, all 4 cardiac chambers enlarge with exercise training, but there
s little evidence of right ventricular dysfunction, except for reversible,
ransient changes after endurance events (3)—which might be related
o a number of factors, such as elevations in heart rate, plasma volume
lterations, or desensitization of beta-adrenoceptors. Furthermore, the
bservations that cTn is elevated after low-intensity exercise such as
alking (4), early during a treadmill marathon (5), and after 30 min
f high-intensity running (6) suggest that cTn elevations are common
ith exercise and not necessarily a product of prolonged effort. Recent
tudies have also shown no relationship between exercise-induced cTn
elease and late gadolinium enhancement with cardiac magnetic
esonance imaging (7) and that, unlike acute coronary syndromes, cTn
apidly returns to baseline after exercise. In combination, such
bservations suggest a benign event. Finally, we would caution Dr.
arper as he has us: in the absence of longitudinal studies, it is
rovocative and premature to suggest that right ventricular problems
bserved in a case series of endurance athletes are produced by their
thletic participation.
